Daxor Corporation (NASDAQ:DXR) Short Interest Update

Daxor Corporation (NASDAQ:DXR) was the target of a large growth in short interest in March. As of March 13th, there was short interest totaling 9,006 shares, a growth of 149.8% from the February 26th total of 3,605 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average trading volume of 16,592 shares, the days-to-cover ratio is currently 0.5 days. Based on an average trading volume of 16,592 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.4% of the company’s stock are short sold.

Daxor Stock Performance

Shares of DXR opened at $10.35 on Wednesday. The company has a 50 day moving average of $12.15 and a two-hundred day moving average of $12.68. Daxor has a twelve month low of $7.10 and a twelve month high of $14.76.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DXR. Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research report on Monday, December 29th. Lake Street Capital assumed coverage on Daxor in a research note on Wednesday, February 11th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Daxor has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Daxor stock. Osaic Holdings Inc. bought a new stake in shares of Daxor Corporation (NASDAQ:DXR) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 8,750 shares of the company’s stock, valued at approximately $86,000. Osaic Holdings Inc. owned approximately 0.18% of Daxor at the end of the most recent reporting period. Institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA‐100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA‐100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.